CSIMarket
 


Kymera Therapeutics Inc   (KYMR)
Other Ticker:  
 
 

KYMR's Revenue Growth by Quarter and Year

Kymera Therapeutics Inc 's Revenue results by quarter and year




KYMR Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 9.55 18.52 0.00
III Quarter September 4.73 11.51 18.70 0.00
II Quarter June 16.51 9.62 -14.53 0.00
I Quarter March 9.47 20.34 14.53 0.00
FY   30.71 51.02 37.22 0.00



KYMR Revenue third quarter 2022 Y/Y Growth Comment
Kymera Therapeutics Inc reported drop in Revenue in the third quarter 2022 by -58.92% to $ 4.73 millions, from the same quarter in 2021.
The fall in the third quarter 2022 Kymera Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue decrease of -8.11%.

Looking into third quarter 2022 results within Biotechnology & Pharmaceuticals industry 12 other companies have achieved higher Revenue growth. While Kymera Therapeutics Inc ' s Revenue meltdown of -58.92% ranks overall at the positon no. 1309 in the third quarter 2022.




KYMR Revenue ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - -48.43 % - -
III Quarter September -58.92 % -38.45 % - -
II Quarter June 71.62 % - - -
I Quarter March -53.44 % 39.99 % - -
FY   - 37.08 % - -

Financial Statements
Kymera Therapeutics Inc 's third quarter 2022 Revenue $ 4.73 millions KYMR's Income Statement
Kymera Therapeutics Inc 's third quarter 2021 Revenue $ 11.51 millions Quarterly KYMR's Income Statement
New: More KYMR's historic Revenue Growth >>


KYMR Revenue (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -17.03 % -0.96 % -
III Quarter September -71.36 % 19.65 % - -
II Quarter June 74.34 % -52.7 % - -
I Quarter March -0.84 % 9.83 % - -
FY (Year on Year)   - 37.08 % - -




Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #149
Overall #1309

Revenue Y/Y Growth Statistics
High Average Low
37.08 % -8.11 % -32.89 %
(Sep 30 2022)   (Sep 30 2023)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #149
Overall #1309
Revenue Y/Y Growth Statistics
High Average Low
37.08 % -8.11 % -32.89 %
(Sep 30 2022)   (Sep 30 2023)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Kymera Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
74.45 % 2.42 % -71.37 %
(Jun 30 2023)  


KYMR's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Kymera Therapeutics Inc reported fall in Revenue from the second quarter by -71.36% to $ 4.73 millions, from $ 16.51 millions released in the previous reporting period.

Albeit seasonal influence usually energize III. Quarter 2022 Revenue, it clearly was not enough to salvage Kymera Therapeutics Inc 's III. Quarter 2022 outcome, Luca  Wood, a business contributor based in London pointed out and continued that average quarter on quarter Revenue growth is at 2.42% for KYMR.

Within Biotechnology & Pharmaceuticals industry 81 other companies have achieved higher Revenue quarter on quarter growth. While Kymera Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3790.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #82
Healthcare Sector #620
Overall #3790
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #82
Healthcare Sector #620
Overall #3790
Revenue Q/Q Growth Statistics
High Average Low
74.45 % 2.42 % -71.37 %
(Jun 30 2023)  


KYMR's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Kymera Therapeutics Inc realized fall in Revenue sequentially by -71.36% to $ 4.73 millions, from $ 16.51 millions achived in the previous reporting period.

Although seasonal influence normally elevate III. Quarter 2022 performance, it plainly could not be enough to rescue Biotechnology & Pharmaceuticals's company III. Quarter performance, Luca  Wood, a business contributor based in London said.

Within Biotechnology & Pharmaceuticals industry 81 other companies have achieved higher Revenue quarter on quarter growth. While Kymera Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3790.


Kymera Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
Cumulative Revenue 12 Months Ending $ 40.26 $ 47.04 $ 40.15 $ 51.02 $ 59.99
Y / Y Revenue Growth (TTM) -32.89 % -29.97 % -6.67 % 37.08 % -
Year on Year Revenue Growth Overall Ranking # 128 # 557 # 221 # 433 # 0
Seqeuential Revenue Change (TTM) -14.42 % 17.16 % -21.3 % -14.95 % -10.7 %
Seq. Revenue Growth (TTM) Overall Ranking # 1309 # 410 # 1303 # 2089 # 1045




Cumulative Revenue growth Comment
Kymera Therapeutics Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -32.89% year on year, at Sep 30 2023 compare to the -29.97% decrease at Jun 30 2023. If the Kymera Therapeutics Inc 's fiscal year would end at Sep 30 2023, annual Revenue would be $40 millions.

In the Healthcare sector 35 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 128, from total ranking in previous quarter at 557.

Revenue TTM Q/Q Growth Statistics
High Average Low
37.08 %
-8.11 %
-32.89 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 13
Healthcare Sector # 36
Overall # 128

Revenue TTM Y/Y Growth Statistics
High Average Low
37.08 %
-8.11 %
-32.89 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 149
S&P 500 # 1309
Cumulative Revenue growth Comment
Kymera Therapeutics Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -32.89% year on year, at Sep 30 2023 compare to the -29.97% decrease at Jun 30 2023. If the Kymera Therapeutics Inc 's fiscal year would end at Sep 30 2023, annual Revenue would be $40 millions.

In the Healthcare sector 35 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 128, from total ranking in previous quarter at 557.

Revenue TTM Q/Q Growth Statistics
High Average Low
37.08 %
-8.11 %
-32.89 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 13
Healthcare Sector # 36
Overall # 128

Revenue TTM Y/Y Growth Statistics
High Average Low
37.08 %
-8.11 %
-32.89 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 149
S&P 500 # 1309




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
KYMR's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for KYMR's Competitors
Revenue Growth for Kymera Therapeutics Inc 's Suppliers
Revenue Growth for KYMR's Customers

You may also want to know
KYMR's Annual Growth Rates KYMR's Profitability Ratios KYMR's Asset Turnover Ratio KYMR's Dividend Growth
KYMR's Roe KYMR's Valuation Ratios KYMR's Financial Strength Ratios KYMR's Dividend Payout Ratio
KYMR's Roa KYMR's Inventory Turnover Ratio KYMR's Growth Rates KYMR's Dividend Comparisons



Companies with similar Revenue drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Procyon Corporation-0.22%$ -0.221 millions
Amedisys Inc -0.31%$ -0.314 millions
Karyopharm Therapeutics Inc -0.38%$ -0.376 millions
Establishment Labs Holdings Inc -0.50%$ -0.505 millions
Opko Health Inc -0.64%$ -0.639 millions
Integra Lifesciences Holdings Corp-0.72%$ -0.719 millions
Healthcare Services Group Inc -0.75%$ -0.748 millions
Phibro Animal Health Corporation-0.77%$ -0.772 millions
Bellicum Pharmaceuticals Inc -0.89%$ -0.890 millions
Prestige Consumer Healthcare Inc -1.12%$ -1.125 millions
Sharecare Inc -1.13%$ -1.127 millions
Lifevantage Corp-1.14%$ -1.140 millions
Organon and Co -1.17%$ -1.171 millions
Optinose Inc -1.27%$ -1.270 millions
Baxter International Inc -1.72%$ -1.723 millions
Puma Biotechnology Inc -1.73%$ -1.727 millions
Blueprint Medicines Corporation-1.76%$ -1.763 millions
Standard Biotools Inc -1.92%$ -1.918 millions
Pacira Biosciences inc -2.11%$ -2.114 millions
Bristol myers Squibb Company-2.25%$ -2.246 millions
Aurinia Pharmaceuticals Inc -2.27%$ -2.266 millions
Abbott Laboratories-2.56%$ -2.565 millions
Enhabit Inc -2.79%$ -2.785 millions
Novocure Limited-2.81%$ -2.807 millions
Uniqure N v -2.90%$ -2.899 millions
Vaso Corporation-2.92%$ -2.925 millions
Scientific Industries Inc -3.16%$ -3.165 millions
Akumin Inc -3.21%$ -3.205 millions
Syros Pharmaceuticals Inc -3.32%$ -3.315 millions
Viatris Inc -3.34%$ -3.342 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com